<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01295788</url>
  </required_header>
  <id_info>
    <org_study_id>CHEO 09/05E</org_study_id>
    <nct_id>NCT01295788</nct_id>
  </id_info>
  <brief_title>Timing of Initiation of Continuous Glucose Monitoring in Established Pediatric Diabetes (The CGM TIME Trial)</brief_title>
  <official_title>Simultaneous vs Delayed Initiation of REAL-Time Continuous Glucose Monitoring in Children and Adolescents With Type 1 Diabetes Starting Insulin Pump Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital of Eastern Ontario</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Juvenile Diabetes Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Canadian Clinical Trial Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Hospital of Eastern Ontario</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators hypothesize that REAL-Time Continuous Glucose Monitoring (RT-CGM) will be&#xD;
      more effective if introduced in children and adolescents with established diabetes at the&#xD;
      same time as they are starting pump therapy. This randomized controlled trial will compare&#xD;
      the effectiveness of simultaneous vs delayed introduction of RT-CGM in children and&#xD;
      adolescents with type 1 diabetes who are starting insulin pump therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      REAL-Time Continuous Glucose Monitoring (RT-CGM) improves diabetes control in adults with&#xD;
      type 1 diabetes. However, studies of RT-CGM in children and adolescents have been mostly&#xD;
      negative. The lack of effectiveness in the pediatric population appears directly related to&#xD;
      adherence to RT-CGM, i.e., the willingness of children and teens to wear and use this&#xD;
      technology. Most previous RT-CGM studies have focused on experienced pump users or children&#xD;
      with new-onset diabetes. At the time of pump initiation, children and adolescents who have&#xD;
      been living with diabetes (and their parents) are highly motivated to make changes in their&#xD;
      diabetes management and to take on additional responsibilities to improve their diabetes&#xD;
      control and lifestyle, the two primary reasons for initiating pump therapy in the pediatric&#xD;
      population. The investigators hypothesize that readiness for making changes in diabetes&#xD;
      management will be greater at the time of pump initiation than at six months after the pump&#xD;
      start. Further, the investigators hypothesize that readiness for change at the time of RT-CGM&#xD;
      initiation will predict future adherence to RT-CGM and its effectiveness.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 2011</start_date>
  <completion_date type="Actual">December 2017</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Simultaneous or Delayed initiation of continuous glucose monitoring</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adherence to CGM (hours per week)</measure>
    <time_frame>one year</time_frame>
    <description>Number of hours of RT-CGM use per week</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>A1C</measure>
    <time_frame>one year</time_frame>
    <description>Hemoglobin A1C</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Readiness for change</measure>
    <time_frame>six months</time_frame>
    <description>SOCRATES - Diabetes Version</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Satisfaction and Quality of Life</measure>
    <time_frame>one year</time_frame>
    <description>Insulin Delivery Systems Rating Questionnaire (IDSRQ)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fear of Hypoglycemia</measure>
    <time_frame>one year</time_frame>
    <description>Hypoglycemia Fear Scale (HFS-98)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Barriers to Adherence</measure>
    <time_frame>one year</time_frame>
    <description>Modified Barriers to Adherence Questionnaire (MBAQ)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perception of Barriers/Facilitators to RT-CGM Use</measure>
    <time_frame>one year</time_frame>
    <description>CGM Satisfaction Scale (CGM-SAT)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">144</enrollment>
  <condition>Type 1 Diabetes</condition>
  <arm_group>
    <arm_group_label>Simultaneous RT-CGM and Pump Initiation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The experimental group will initiate RT-CGM at the same time as they begin insulin pump therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Delayed RT-CGM Initiation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The control group will use standard pump therapy until the 6 month study visit at which time RT-CGM will be initiated.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Simultaneous RT-CGM and Pump Initiation</intervention_name>
    <description>Subjects in this group will start using RT-CGM at the same time as they initiate insulin pump therapy.</description>
    <arm_group_label>Simultaneous RT-CGM and Pump Initiation</arm_group_label>
    <other_name>Sensor-Augmented Pump Therapy at Pump Initiation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Delayed Initiation of RT-CGM</intervention_name>
    <description>Subjects in this group will start using RT-CGM 6 months after initiation of insulin pump therapy.</description>
    <arm_group_label>Delayed RT-CGM Initiation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Males and females age 5-18 years old.&#xD;
&#xD;
          -  Established T1D diagnosis for a minimum of one year.&#xD;
&#xD;
          -  Na√Øve to CSII therapy and ready to start CSII with the Veo pump (Medtronic) .&#xD;
&#xD;
          -  Willing to use RT-CGM and to be randomly assigned to either simultaneous or delayed&#xD;
             RT-CGM initiation.&#xD;
&#xD;
          -  Regular diabetes follow up at one of the 5 participating sites.&#xD;
&#xD;
          -  Internet access at home (to upload RT-CGM data).&#xD;
&#xD;
          -  Parent(s) or legally acceptable representative able to speak and read English or&#xD;
             French.&#xD;
&#xD;
          -  Ability of the subject and parent(s) or legally acceptable representative to&#xD;
             participate in all aspects of this clinical trial.&#xD;
&#xD;
          -  Written informed consent must be obtained and documented, with assent of the child if&#xD;
             &lt;14 years of age.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Conditions which in the opinion of the investigator may interfere with the subject's&#xD;
             ability to participate in the study.&#xD;
&#xD;
          -  Has received oral and/or intravenous steroid therapy (for any indication, at any dose&#xD;
             and/or for any duration) on more than 2 separate occasions in the past 12 months. Use&#xD;
             of inhaled and/or topical steroid therapy in the last 12 months does not exclude the&#xD;
             subject.&#xD;
&#xD;
          -  Prior use of RT-CGM for more than 50% of the time over the past 6 months.&#xD;
&#xD;
          -  Prior enrollment in the current study.&#xD;
&#xD;
          -  Current enrollment in another intervention trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Margaret L Lawson, MD</last_name>
    <role>Study Director</role>
    <affiliation>Children's Hospital of Eastern Ontario</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>McMaster Children's Hospital</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8S 4J9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Western Ontario</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N5Y 3T2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Markham-Stouffville Hospital</name>
      <address>
        <city>Markham</city>
        <state>Ontario</state>
        <zip>L3P 7P3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Eastern Ontario</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital for Sick Children</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <results_reference>
    <citation>Lawson ML, Verbeeten KC, Courtney JM, Bradley BJ, McAssey K, Clarson C, Kirsch S, Curtis JR, Mahmud FH, Richardson C, Cooper T, Chan J, Tang K. Timing of CGM initiation in pediatric diabetes: The CGM TIME Trial. Pediatr Diabetes. 2021 Mar;22(2):279-287. doi: 10.1111/pedi.13144. Epub 2020 Nov 4.</citation>
    <PMID>33098212</PMID>
  </results_reference>
  <results_reference>
    <citation>Verbeeten KC, Perez Trejo ME, Tang K, Chan J, Courtney JM, Bradley BJ, McAssey K, Clarson C, Kirsch S, Curtis JR, Mahmud FH, Richardson C, Cooper T, Lawson ML; CGM TIME Trial Study Group and the JDRF Canadian Clinical Trials Group. Fear of hypoglycemia in children with type 1 diabetes and their parents: Effect of pump therapy and continuous glucose monitoring with option of low glucose suspend in the CGM TIME trial. Pediatr Diabetes. 2021 Mar;22(2):288-293. doi: 10.1111/pedi.13150. Epub 2020 Nov 27.</citation>
    <PMID>33179818</PMID>
  </results_reference>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>February 14, 2011</study_first_submitted>
  <study_first_submitted_qc>February 14, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 15, 2011</study_first_posted>
  <last_update_submitted>May 28, 2021</last_update_submitted>
  <last_update_submitted_qc>May 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Children's Hospital of Eastern Ontario</investigator_affiliation>
    <investigator_full_name>Margaret Lawson</investigator_full_name>
    <investigator_title>Professor of Pediatrics</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

